Semax vs Selank: Focus vs Calm — What the Evidence Actually Shows

Semax and Selank are the two "brain peptides" that have crossed from Russian clinics into Western biohacking and athletic stacks — and athletes reach for them for the mental side of performance: sharper focus and drive under fatigue (Semax), or calmer nerves and lower competition anxiety (Selank). They're usually sold as nasal sprays, marketed as cleaner alternatives to stimulants and benzodiazepines, and pitched as if their effects are well established. The reality is more nuanced, and the most important fact about both is one the marketing rarely states plainly.

Honest headline first: Semax and Selank are genuine, decades-old Russian peptide drugs — both are actually approved and clinically used in Russia — but almost their entire human evidence base comes from Russian-language studies that have not been replicated to Western regulatory standards, and much of the mechanistic data is in animals. Semax leans "focus, drive, neuroprotection"; Selank leans "anti-anxiety, calm." Neither is FDA-approved, neither has Western-grade trial evidence for athletic performance, and both are sold to Westerners as grey-market research chemicals. Choosing between them is choosing between two under-validated tools — useful framing, not a green light.

The Core Difference: Drive vs Calm

The single most useful way to separate these two is by direction of effect.

Semax is a synthetic analog of a fragment of ACTH (adrenocorticotropic hormone) — specifically a modified ACTH(4-10) sequence. It was developed in Russia as a nootropic and neuroprotective drug, and its reputation is for activation: focus, mental stamina, and protection of brain tissue under stress. The mechanistic story centers on the brain's growth factors — Semax has been shown to regulate BDNF (brain-derived neurotrophic factor) and its receptor TrkB in the rat hippocampus¹, the same neuroplasticity machinery tied to learning and resilience, and it attenuated behavioral and neurochemical disturbances in animal stress models². For an athlete, that maps onto the pitch of "switch-on" focus and drive.

Selank points the other way. It's a synthetic analog of the immune peptide tuftsin, developed in Russia as an anxiolytic — an anti-anxiety agent meant to calm without the sedation, dependence, and cognitive dulling of benzodiazepines. Its mechanistic work spans GABA/serotonin signaling and the immune system: Selank has been shown to influence the expression of cytokines and their receptors³, and related tuftsin-analog work documented anti-anxiety effects in animal models⁴. For an athlete, Selank's pitch is competition-day calm and stress resilience without feeling drugged.

So in one line: Semax is the "focus/drive" peptide; Selank is the "calm/anti-anxiety" peptide. That genuine functional split is the most defensible thing in this entire comparison.

The Evidence Problem They Both Share

Here's the part that matters more than the focus-vs-calm distinction, and the part the marketing flattens: the human evidence for both peptides is overwhelmingly Russian, older, and not replicated to the standards Western regulators require.

Both drugs are genuinely approved and used in Russia — Semax for stroke and cognitive indications, Selank for anxiety — and there is human clinical literature. On the Semax side, studies report efficacy in patients at different stages of ischemic stroke⁵. On the Selank side, a clinical study reported efficacy in the treatment of generalized anxiety disorder⁶. These are real human studies, and it would be wrong to dismiss them as nonexistent.

But it would be equally wrong to treat them as settled science. The bulk of this literature is published in Russian-language journals, often with small samples and study designs that haven't been reproduced in independent Western trials or subjected to the regulatory scrutiny that FDA or EMA approval demands. Much of the mechanistic support — the BDNF effects, the anxiolytic action, the neuroprotection — comes from rodent studies¹²⁴. None of it tests the specific thing athletes are buying these for: a demonstrated improvement in athletic focus, competition performance, or training recovery in healthy, trained people. That trial simply doesn't exist for either compound. The same "interesting mechanism, missing the trial that matters" pattern runs through this whole category — see our pillar on GH peptides and recovery and our review of peptides for recovery and healing.

Head-to-Head: Which One for Which Goal?

Within the honest limits above, here's how the two actually compare for an athlete's use case.

Choose the Semax profile if your problem is focus and drive — mental fatigue late in a session, difficulty locking in, or wanting cognitive sharpness without a stimulant's jitter. Semax's animal and Russian-clinical data center on cognition, BDNF, and neuroprotection. Choose the Selank profile if your problem is anxiety and stress — pre-competition nerves, racing thoughts, stress that disrupts sleep or recovery. Selank's data centers on anxiolysis without sedation. Some users stack them (Selank to take the edge off, Semax for focus), but understand that combining two under-validated peptides multiplies the uncertainty rather than resolving it — there's no trial of the combination, in athletes or anyone else.

It's worth being blunt about expectations. Even taking the Russian data at face value, these are subtle agents, not stimulants or sedatives — the reported effects are modulatory, not dramatic. Anyone expecting a clear, reliable performance boost is likely projecting the marketing onto a molecule whose real-world athletic effect has never been measured.

Nasal Sprays, Dosing, and the Grey-Market Reality

Both are most commonly sold as intranasal sprays — a route that makes sense given they're peptides (which oral digestion would destroy) and that nasal delivery may reach the brain. But the "dosing protocols" floating around are extrapolated from Russian clinical use and community practice, not from Western dose-finding trials for athletic or cognitive enhancement in healthy people. There is no validated athletic dose for either, because the athletic benefit they'd be dosed for has never been established in a controlled trial.

And the supply problem is acute. Neither Semax nor Selank is an FDA-approved drug; in the West, both are sold "for research use only" by grey-market vendors, meaning you cannot verify identity, purity, concentration, or sterility — a real, independent safety problem on top of the thin efficacy data. Nasal peptide products add their own contamination and formulation concerns. We cover how to vet what you're actually buying in our guide to verifying a peptide's certificate of analysis and the vendor red flags worth knowing first.

The Anti-Doping Angle

Neither Semax nor Selank is a famous named target on the WADA Prohibited List the way GH secretagogues or IGF-1 are, but a tested athlete should not read that as "safe." Anti-doping rules cover broad classes (including, for example, substances acting on brain pathways or with stimulant-like effects), the prohibited list evolves, and — critically — a grey-market "research" product of unverifiable composition can contain something other than what's on the label. You cannot be confident an unregulated nasal peptide won't trigger a violation or contain a contaminant that does. Any drug-tested athlete should treat these as high-risk and verify status before use; our prohibited-substance checker gives a per-compound answer, and our guide to whether GH peptides are safe and legal and our review of whether peptides show up on drug tests lay out how to think about it.

One wrinkle is worth naming, because it cuts both ways. Semax holds a marketing authorization in Russia, and WADA's catch-all category for non-approved substances applies only to compounds with no approval by any government health authority — so a Russian authorization arguably keeps Semax outside that particular net. Arguably is not a defence at a hearing, and it says nothing about the other categories or about what is actually in a grey-market vial. That regulatory picture, including the July 2026 FDA advisory vote that reviewed Semax for stroke and migraine rather than for focus, is in Semax FDA status.

Bottom Line

Semax and Selank are real Russian peptide drugs with a genuine functional split: Semax for focus, drive, and neuroprotection; Selank for calm and anti-anxiety. That distinction is the most defensible thing about them, and both have legitimate Russian human clinical use behind them. If you must choose, choose by problem — drive (Semax) or anxiety (Selank).

But the honest verdict on both is the same: their human evidence is overwhelmingly Russian-language, older, small, and unreplicated to Western standards, their mechanistic support is heavily animal-based, and neither has a controlled trial showing it improves athletic focus, performance, or recovery in healthy, trained people. Add the unapproved status, the unverifiable grey-market supply, and the anti-doping uncertainty for tested athletes, and the picture is clear: these are intriguing, under-validated cognitive peptides — not proven performance tools. For where they and the rest of the field rank on real evidence, see our evidence-ranked guide to the best recovery peptides.